Our results showed that SDF-1/54 remained at a high level of antiviral potency against HIV-1 infection and that the presence of vaginal fluid simulant, seminal fluid and HSA had no significant effects on the antiviral potency of SDF-1/54, suggesting that SDF-1/54 is suitable for further development as an effective and safe anti-HIV agent. The gene discussed is CXCL12; the disease is HIV-1 infection.